Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BLU-808 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Arm A1 (Part A): BLU-808 | EXPERIMENTAL | BLU-808 will be administered orally. |
| Arm A3 (Part A): BLU-808 | EXPERIMENTAL | BLU-808 will be administered orally. |
| Arm B (Part B): BLU-808/Placebo | EXPERIMENTAL | BLU-808 or matching placebo will be administered orally. |
| BLU-808 Dose 1 | EXPERIMENTAL | BLU-808 will be administered orally for 28 days. |
| BLU-808 Dose 2 | EXPERIMENTAL | BLU-808 will be administered orally for 28 days. |
| Placebo | PLACEBO_COMPARATOR | Placebo will be administered orally for 28 days. |
| Name | Type | Description |
|---|---|---|
| BLU-808 | DRUG | Oral administration |
| Placebo | DRUG | Oral administration |
Key Inclusion Criteria: * Part A: Confirmed diagnosis of CIndU for ≥3 months prior to Day 1 that is inadequately controlled with second generation H1-antihistamines. * Part B: Confirmed diagnosis of CSU for ≥3 months prior to Day 1 that is inadequately controlled with second generation H1-antihista...
BLU-808 is an investigational small molecule being developed by Blueprint Medicines Corporation for allergic and inflammatory conditions. It is in Phase 2 clinical development for allergic rhinoconjunctivitis and for chronic inducible urticaria, including chronic spontaneous urticaria. It has not been approved by the FDA and remains under clinical study.
BLU-808 is being studied as a treatment for allergic rhinoconjunctivitis, an allergic condition affecting the nose and eyes. A Phase 2 trial of BLU-808 in allergic rhinoconjunctivitis has been completed in Canada. The drug is investigational and is not approved for this or any other indication.
Blueprint Medicines Corporation, which trades on the Nasdaq under the ticker BPMC, is developing BLU-808. The company is the sponsor of the clinical trials evaluating the drug in allergic rhinoconjunctivitis and in chronic urticaria. BLU-808 is an investigational small molecule and has not received FDA approval.
BLU-808 is in Phase 2 clinical development. Two Phase 2 trials have been run: one in allergic rhinoconjunctivitis, which is completed, and one in chronic inducible urticaria and chronic spontaneous urticaria, which is active and not recruiting. BLU-808 is investigational and has not been approved by the FDA.
BLU-808 has been evaluated in two Phase 2 trials. NCT06922448 studied BLU-808 in allergic rhinoconjunctivitis in Canada and is completed. NCT06931405 is studying BLU-808 in chronic inducible urticaria and chronic spontaneous urticaria across the United States, Denmark, Germany, Italy, Spain, and Taiwan, and is active but not recruiting.
BLU-808 is a small molecule drug candidate. It is being developed for allergic and urticarial conditions, including allergic rhinoconjunctivitis and chronic inducible urticaria. Its precise molecular target has not been publicly characterized in the available trial information, and it remains an investigational agent in Phase 2 testing.